Tonix Pharmaceuticals (US:TNXP) Globenewswire·2025-10-14 11:00Core Insights - Tonix Pharmaceuticals is advancing its immunomodulatory candidate TNX-1500, targeting CD40-ligand (CD40L) to prevent organ transplant rejection and treat autoimmune diseases, as highlighted in a recent presentation by CEO Dr. Seth Lederman at the Japan Society for Transplantation Congress [1][2]. Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company with marketed products and a pipeline of development candidates, including TNX-1500, which is designed to inhibit CD40L [4][5]. - The company has received FDA approval for Tonmya™, a non-opioid analgesic for fibromyalgia, marking the first new prescription medicine approval for this condition in over 15 years [5][6]. Product Development - TNX-1500 is an investigational humanized monoclonal antibody aimed at preventing allograft and xenograft rejection, as well as treating graft-versus-host disease (GvHD) and autoimmune diseases [4][6]. - The Phase 1 study of TNX-1500 showed favorable safety and biomarker data, supporting its continued development [2][4]. - The design of TNX-1500 aims to minimize thromboembolic risk while maintaining immunomodulatory activity, with plans for Phase 2 studies focusing on kidney transplant rejection and autoimmune indications [2][4]. Scientific Recognition - The presentation at the congress coincided with the awarding of the 2025 Nobel Prize in Physiology or Medicine to researchers who discovered T-regulatory cells, which are significant in immune response and organ transplant success [2][3]. Collaborative Efforts - The presentation included insights from academic collaborators, emphasizing the importance of CD154/CD40 blockade in transplantation, showcasing Tonix's engagement with the scientific community [3].